Dapagliflozin effectiveness in improvement of clinical outcomes in diabetic patients (extention of CARDIA-MOS study, Moscow)
OBJECTIVES. Dapagliflozin is a glucose-lowering drug of the class of type 2 sodium-glucose cotransporter inhibitors (iSGLT-2) that also has cardio- and nephroprotective properties. Its efficacy in improving cardiovascular and renal outcomes in patients with type 2 diabetes mellitus (T2D) is well stu...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2025-02-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/13262 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|